Rankings
▼
Calendar
MESO
Mesoblast Limited
$2B
Q3 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4M
Gross Profit
-$4M
-86.4% margin
Operating Income
-$20M
-494.0% margin
Net Income
-$17M
-408.8% margin
EPS (Diluted)
$-0.31
QoQ Revenue Growth
+3.2%
Cash Flow
Operating Cash Flow
-$22M
Free Cash Flow
-$22M
Stock-Based Comp.
$579,000
Balance Sheet
Total Assets
$770M
Total Liabilities
$291M
Stockholders' Equity
$479M
Cash & Equivalents
$11M
← FY 2016
All Quarters
Q4 2016 →
MESO Q3 2016 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena